FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3198260858> ?p ?o ?g. }

• W3198260858 endingPage "e2123930" @default.
• W3198260858 startingPage "e2123930" @default.
• W3198260858 abstract "Developmental and epileptic encephalopathies (DEEs) are the most severe group of drug-resistant epilepsies. Alternatives to oral therapies are urgently needed to reduce seizures and improve developmental outcomes and comorbidities in this medically complex population.To assess the safety and tolerability of cannabidiol (CBD) transdermal gel in children with DEEs and to evaluate seizure frequency, sleep, and quality of life.This nonrandomized controlled trial was conducted in 2 centers in Australia and New Zealand from April 2018 to July 2019. Children and adolescents aged 3 to 18 years with DEEs who were receiving a stable regimen of 1 to 4 antiseizure medications were eligible for this study. After 1-month baseline and titration periods, patients entered a 5.5-month flexible-dosing maintenance period for a total of 6.5 months of treatment. Data were analyzed throughout the 6.5-month treatment period.Twice-daily applications of CBD transdermal gel at doses of 125 to 500 mg for 6.5 months.Safety and tolerability assessments included adverse events (AEs) and examination of skin. The outcome for seizures was the median percentage change from baseline in monthly (28-day) seizure frequency of focal impaired awareness seizures (FIAS) and tonic-clonic seizures (TCS) over 6.5 months.Of 48 patients (mean [SD] age, 10.5 [3.8] years; 26 [54%] boys), 29 (60%) had at least 1 treatment-related AE over 6.5 months; 44 of 46 treatment-related AEs (96%) were mild or moderate. Treatment-related AEs that occurred in at least 5% of patients were application-site dryness, application-site pain, and somnolence (each reported by 4 patients [8%]). The only treatment-related gastrointestinal AE was diarrhea, reported in a single patient. CBD treatment was associated with reductions in FIAS and TCS frequency. Analysis of the 33 patients with FIAS and TCS showed a median (interquartile range) monthly reduction in seizures of 58% (-5.3% to 81.8%) at 5 months and 43.5% (-23.8% to 57.5%) over the entire 6.5-month study period. Parents and caregivers noted improvements in social or interpersonal engagement and irritability (33 of 43 [77%] participants); alertness, energy, and sleep (23 of 43 [53%]); and cognition or concentration (20 of 43 [47%]).In this study, CBD transdermal gel was safe, well tolerated, and was associated with reductions in FIAS and TCS frequency and disease burden.ClinicalTrials.gov Identifier: ACTRN12618000516280." @default.
• W3198260858 created "2021-09-13" @default.
• W3198260858 creator A5000684540 @default.
• W3198260858 creator A5002562692 @default.
• W3198260858 creator A5004461693 @default.
• W3198260858 creator A5015274629 @default.
• W3198260858 creator A5041159807 @default.
• W3198260858 creator A5046530664 @default.
• W3198260858 creator A5059269866 @default.
• W3198260858 creator A5060064352 @default.
• W3198260858 creator A5079007515 @default.
• W3198260858 date "2021-09-03" @default.
• W3198260858 modified "2023-10-10" @default.
• W3198260858 title "Safety and Tolerability of Transdermal Cannabidiol Gel in Children With Developmental and Epileptic Encephalopathies" @default.
• W3198260858 cites W1166458116 @default.
• W3198260858 cites W2030991703 @default.
• W3198260858 cites W2127095924 @default.
• W3198260858 cites W2136509920 @default.
• W3198260858 cites W2145664048 @default.
• W3198260858 cites W2211460847 @default.
• W3198260858 cites W2482013914 @default.
• W3198260858 cites W2585652737 @default.
• W3198260858 cites W2620218661 @default.
• W3198260858 cites W2670295943 @default.
• W3198260858 cites W2736365965 @default.
• W3198260858 cites W2767798785 @default.
• W3198260858 cites W2785059893 @default.
• W3198260858 cites W2791384105 @default.
• W3198260858 cites W2804921146 @default.
• W3198260858 cites W2961503558 @default.
• W3198260858 cites W2965554962 @default.
• W3198260858 cites W4229901515 @default.
• W3198260858 cites W4241590657 @default.
• W3198260858 cites W4244769298 @default.
• W3198260858 cites W4244831580 @default.
• W3198260858 cites W4255347079 @default.
• W3198260858 cites W4292528167 @default.
• W3198260858 doi "https://doi.org/10.1001/jamanetworkopen.2021.23930" @default.
• W3198260858 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8417764" @default.
• W3198260858 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34477852" @default.
• W3198260858 hasPublicationYear "2021" @default.
• W3198260858 type Work @default.
• W3198260858 sameAs 3198260858 @default.
• W3198260858 citedByCount "15" @default.
• W3198260858 countsByYear W31982608582022 @default.
• W3198260858 countsByYear W31982608582023 @default.
• W3198260858 crossrefType "journal-article" @default.
• W3198260858 hasAuthorship W3198260858A5000684540 @default.
• W3198260858 hasAuthorship W3198260858A5002562692 @default.
• W3198260858 hasAuthorship W3198260858A5004461693 @default.
• W3198260858 hasAuthorship W3198260858A5015274629 @default.
• W3198260858 hasAuthorship W3198260858A5041159807 @default.
• W3198260858 hasAuthorship W3198260858A5046530664 @default.
• W3198260858 hasAuthorship W3198260858A5059269866 @default.
• W3198260858 hasAuthorship W3198260858A5060064352 @default.
• W3198260858 hasAuthorship W3198260858A5079007515 @default.
• W3198260858 hasBestOaLocation W31982608581 @default.
• W3198260858 hasConcept C118552586 @default.
• W3198260858 hasConcept C126322002 @default.
• W3198260858 hasConcept C187212893 @default.
• W3198260858 hasConcept C197934379 @default.
• W3198260858 hasConcept C2776895053 @default.
• W3198260858 hasConcept C2777056318 @default.
• W3198260858 hasConcept C2777288759 @default.
• W3198260858 hasConcept C2778186239 @default.
• W3198260858 hasConcept C2778375690 @default.
• W3198260858 hasConcept C2781413609 @default.
• W3198260858 hasConcept C2908647359 @default.
• W3198260858 hasConcept C42219234 @default.
• W3198260858 hasConcept C71924100 @default.
• W3198260858 hasConcept C99454951 @default.
• W3198260858 hasConceptScore W3198260858C118552586 @default.
• W3198260858 hasConceptScore W3198260858C126322002 @default.
• W3198260858 hasConceptScore W3198260858C187212893 @default.
• W3198260858 hasConceptScore W3198260858C197934379 @default.
• W3198260858 hasConceptScore W3198260858C2776895053 @default.
• W3198260858 hasConceptScore W3198260858C2777056318 @default.
• W3198260858 hasConceptScore W3198260858C2777288759 @default.
• W3198260858 hasConceptScore W3198260858C2778186239 @default.
• W3198260858 hasConceptScore W3198260858C2778375690 @default.
• W3198260858 hasConceptScore W3198260858C2781413609 @default.
• W3198260858 hasConceptScore W3198260858C2908647359 @default.
• W3198260858 hasConceptScore W3198260858C42219234 @default.
• W3198260858 hasConceptScore W3198260858C71924100 @default.
• W3198260858 hasConceptScore W3198260858C99454951 @default.
• W3198260858 hasIssue "9" @default.
• W3198260858 hasLocation W31982608581 @default.
• W3198260858 hasLocation W31982608582 @default.
• W3198260858 hasLocation W31982608583 @default.
• W3198260858 hasLocation W31982608584 @default.
• W3198260858 hasLocation W31982608585 @default.
• W3198260858 hasOpenAccess W3198260858 @default.
• W3198260858 hasPrimaryLocation W31982608581 @default.
• W3198260858 hasRelatedWork W1968036257 @default.
• W3198260858 hasRelatedWork W2007986200 @default.
• W3198260858 hasRelatedWork W2060644115 @default.
• W3198260858 hasRelatedWork W2090699703 @default.
• W3198260858 hasRelatedWork W2171389860 @default.

• next